Lupin Mira 25 Tablet ER contains Mirabegron 25 mg, a selective β3-adrenoceptor agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge urinary incontinence. Mirabegron acts by relaxing the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, thereby increasing bladder capacity without compromising voiding function. This extended-release formulation ensures a consistent plasma concentration, enhancing therapeutic efficacy and patient compliance. Lupin Mira 25 Tablet ER is typically prescribed for adults experiencing OAB symptoms who may not tolerate or respond adequately to antimuscarinic agents. The medication is generally well-tolerated, with common adverse effects including hypertension, nasopharyngitis, urinary tract infection, and headache. Caution is advised in patients with severe uncontrolled hypertension, as Mirabegron may elevate blood pressure. Dose adjustments may be necessary in patients with renal or hepatic impairment. Concomitant use with drugs metabolized by CYP2D6 should be monitored due to potential interactions. Regular monitoring of blood pressure and symptom improvement is recommended during therapy. Lupin Mira 25 Tablet ER offers a valuable therapeutic option for improving quality of life in patients suffering from OAB by reducing urinary urgency and incontinence episodes.